Us Bancorp \De\ Atara Biotherapeutics, Inc. Transaction History

Us Bancorp \De\

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$1.5 - $3.04 $1,059 - $2,146	706 Added 66.54%	1,767 $2,000
Q1 2023 May 09, 2023	SELL	$2.8 - $5.46 $6,406 - $12,492	-2,288 Reduced 68.32%	1,061 $3,000
Q4 2022 Feb 13, 2023	SELL	$2.85 - $5.18 $12,297 - $22,351	-4,315 Reduced 56.3%	3,349 $10,000
Q3 2022 Oct 27, 2022	BUY	$2.85 - $8.73 $21,506 - $65,876	7,546 Added 6394.92%	7,664 $29,000
Q1 2022 May 11, 2022	SELL	$8.44 - $16.89 $768 - $1,536	-91 Reduced 43.54%	118 $1,000

Q4 2020 Feb 04, 2021	SELL	$12.67 - $26.23 $823 - $1,704	-65 Reduced 23.72%	209 $4,000
Q3 2020 Nov 10, 2020	BUY	$11.92 - $15.87 $774 - $1,031	65 Added 31.1%	274 $4,000
Q2 2020 Aug 07, 2020	SELL	$7.53 - $14.93 $195 - $388	-26 Reduced 11.06%	209 $3,000
Q1 2020 May 13, 2020	SELL	$5.69 - $17.78 $517 - $1,617	-91 Reduced 27.91%	235 $2,000
Q4 2019 Feb 04, 2020	SELL	$10.89 - $16.79 $174 - $268	-16 Reduced 4.68%	326 $5,000
Q3 2019 Nov 08, 2019	BUY	$12.03 - $19.94 $4,114 - $6,819	342 New	342 $5,000

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $781M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.